Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., has raised US $200 million by way of private placement of 13% Senior Secured Notes due 2024.
Canadian investors subscribed ##subscriber ONLY content## million of the private placement.
Morgan Stanley & Co. LLC acted as sole placement agent for the transaction. Goodmans LLP acted as Lead Counsel, Morrison & Foerster LLP acted as U.S. counsel and Solomon Harris acted as Cayman Islands counsel for Ironshore.
Based in Cayman Islands, Ironshore Pharmaceuticals & Development, Inc. is a pharmaceutical company that is leveraging its proprietary technology, DELEXIS, to optimize the delivery of previously approved drug products.
photo credit: Ironshore Pharmaceuticals & Development
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Cansortium files for IPO on CSE - February 11, 2019
- Cycle Capital holds $109M initial close for Cycle Capital IV - February 11, 2019
- City Capital Ventures acquires Redberry - February 8, 2019